Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Egile Nagusiak: Antonio Lacquaniti (Egilea), Patrizio Pasqualetti (Egilea), Teresa Casuscelli di Tocco (Egilea), Susanna Campo (Egilea), Stefania Rovito (Egilea), Maurizio Bucca (Egilea), Antonino Ragusa (Egilea), Paolo Monardo (Egilea)
• Formatua: Liburua
• Argitaratua: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...